About this trial
The goal of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-threatening disease for which HSCT is indicated. These patients are not eligible for other Children's Hospital of Philadelphia IRB approved protocols that utilize CliniMACs technology for T depletion.
Eligibility criteria
Qualifiers
Patients who lack a fully HLA matched sibling and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT) but are not deemed suitable candidates per their treating clinical team for current open institutional protocols using ClinMACs device for CD3+/CD19+ depletion.
Signed informed consent
Lansky or Karnofsky performance ≥60
Hematologic and Organ Function per current institutional SOP.
Disqualifiers
Uncontrolled bacterial, viral or fungal infections
Suitable, fully HLA matched sibling donor
Donor unable to donate peripheral stem cells
Pregnant participants
Trial design
Treatments tested in this trial
- Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)